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Abbreviations 
 
A1AT : alpha-1 antitrypsin, ATCUN : amino terminal Cu(II)-Ni(II)-binding motif, BMP: 
Bone morphogenetic protein, BMPRE: Bone morphogenetic protein response element, 
C/EBPα: CCAAT- enhancer binding protein α, CD: Circular Dichroism, EPO: 
erythropoietin, EPOR: erythropoetin receptor, FP: ferroportin, GAPDH: Glyceraldehyde 3-
phosphate dehydrogenase, GDF15: erythroid factor growth differentiation factor 15, GST: 
glutathione S-transferase, HAMP : Hepcidin antimicrobial peptide, HFE: human 
hemochromatosis protein, HIF1α: Hypoxia inducible factor 1 α, HJV : hemojuvelin, HRE: 
Hypoxia response element, IL-6 : Interleukin-6, IRE : Iron Resposive Element, IRP: Iron 
Regulatory Protein, LB agar plate: Luria-Bertani agar plate, LEAP-1: liver-expressed 
antimicrobial peptide, MALDI TOF : Matrix Assisted Laser Desorption Ionisation Time Of 
Flight, NE: nuclear extract, NLS: Nuclear localisation signal, NMR : Nuclear magnetic 
resonance, PSSM: Position-Specific Scoring Matrix, sHJV: soluble hemojuvelin, SMAD7: 
Mothers against decapentaplegic homolog 7, STAT3: Signal transducer and activator of 
transcription 3, SVM: Support Vector Machine, Tf : Transferrin, TfR : Transferrin receptor, 
TGF-β: Transforming Growth Factor-β, TMPRSS6: Transmembrane protease, serine 6, 
TWSG1: Twisted Gastrulation cytokine 
 
Introduction 
Hepcidin is the key iron regulatory hormone produced mainly in the liver and secreted 
into the blood. It was originally described as Liver Expressed Antimicrobial Protein (LEAP-
1), an antimicrobial peptide exhibiting consistent antifungal but only weak antibacterial 
activity. Shortly after the discovery of hepcidin its fundamental role in iron homeostasis was 
realized. The hormone acts by binding to the iron exporter ferroportin, triggering its 
internalization and intracellular degradation. In the presence of hepcidin enterocytes release 
less iron into the portal system, resulting in downregulation of the iron uptake through the 
intestines. Similarly, hepcidin negatively regulates he macrophage iron export. Due to these 
effects, hepcidin overexpression has been convincingly linked to microcytic anemia. 
Hepcidin is encoded by the HAMP gene and synthesized in hepatocytes as 
preprohepcidin. It is synthesized as an 84 amino acid (AA) preprohormone, and is present in 
the plasma not only as a mature 25 AA peptide, but in a 60 AA prohormone form as well. The 
maturation is facilitated by the serine peptidase furin. The aim of the present report is to 
reveal that prepro- and prohormones have significant interactions with proteins, which may 
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affect the maturation of the hormone in the cell and its cleavage to active hormone in blood. 
Iron is one of the essential trace elements in livig organisms. In vertebrates plasma iron level 
is in the micromolar range and circulating iron is a sociated predominantly with transport 
protein transferrin. The blood iron levels, as well as the saturation of transferrin are frequently 
used indicators of the body iron status. Both iron deficiency and iron overload are potentially 
dangerous conditions, which may cause either anemia, enzyme dysfunctions, or degenerative 
liver, spleen and kidney diseases. The most important organs and tissues involved in the 
regulation of iron stores are the liver, placenta, intestine, and the macrophages. Recent 
findings indicate, that the hormone hepcidin plays a major part in controlling iron 
homeostasis. This peptide is synthesized in the livr as an 84 AA preprohormone, and is 
targeted to the secretion pathway by a 24 AA N-terminal targeting sequence. The resulting 60 
AA prohepcidin is processed further into mature C-terminal 25 AA active peptide. The 
maturation is facilitated by serine protease furin. Furin belongs to the prohormone convertase 
family which recognizes the consensus sequence of R(X/R/K)(X/R/K)R. 
Hepcidin regulates blood iron level through its interaction with ferroportin, an iron 
exporter molecule. Ferroportin is expressed in hepatocytes, duodenal enterocytes, and 
macrophages. After binding hepcidin, ferroportin isnternalized, phosphorylated, 
ubiquitinated, and degraded by the target cells. As a result, hepcidin increases cellular iron 
sequestration, and reduces the iron level in the plasma. Hepcidin-independent regulation is 
also functionally important in vertebrates. Ferroportin expression was shown to be regulated 
translationally by intracellular iron through the IRE/IRP system and transcriptionally by 
heme, and these responses allow macrophages to match their iron export capacity to the 
fluctuating iron and heme load caused by episodic erythrophagocytosis. There are two major 
isoforms of ferroportin: FPN 1A, with a 5’IRE for tanslational repression in iron-deficient 
cells, and FPN 1B, lacking this motif. FPN 1B is expressed in duodenal enterocytes where it 
may allow them to export iron to the rest of the organism even if the enterocytes become iron-
deficient. 
The known signals for the induction of hepcidin synthesis are the elevation of plasma 
iron level, inflammations, and bacterial invasions. Consequently hepcidin increases iron 
sequestration and lowers the iron level in the blood. A structure-function study suggests that 
the N-terminus of hepcidin is essential for its interaction with ferroportin.  
Mass spectrometry and chemical analysis revealed that the hepcidin peptide contains 8 
conserved cysteines which are all involved in disulfide bonds. Three-dimensional nuclear 
magnetic resonance (3D-NMR) studies of the 20 and 25 amino acid form of hepcidin show 
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that their structure is a simple hairpin with eight cysteines that form four disulfide bonds in a 
ladder-like configuration, including an unusual disulfide bond that connects two adjacent 
cysteines (vicinal disulfide bridge). The peptide has an antiparallel β-sheet with a markedly 
amphipathic structure. The disulfide bond connectivity is a key determinant of the correct 
folding of the peptide and may have a critical role in hepcidin function.  
The NMR structure of hepcidin-25 at different temperatures and its disulfide 
connectivity has been recently revised. Structural studies have shown that removal of 
individual disulfide bonds by pairwise substitution of cysteines with alanines, is quite 
permissive to changes, because the peptides exhibited almost full activity in vitro. Moreover, 
removal of disulfide bonds one at a time did not cause major changes in the peptide structure 
when analyzed by circular dichroism spectroscopy.  
The N-terminal region of hepcidin-25 represents a metal binding site specific for the 
coordination of Cu(II) and Ni(II) known as ATCUN motif, and recently the great affinity of 
the N-terminal region of Hepcidin-25 for the copper has been confirmed. Although it is still 
not known the biological role of a metal binding motif in the hepcidin-25, its presence may be 
physiologically relevant, because has been recently demonstrated that the first five amino 
acids, starting from the N-terminus (DTHFP) are essential but not sufficient for its interaction 
with ferroportin, since their serial deletion, up to hepcidin-20, resulted in a gradual loss of 
activity. 
Under physiological conditions the expression of the HAMP gene in the liver is 
modulated by numerous factors. The known positive regulators are the hereditary 
hemochromatosis protein (HFE), transferrin receptor 2 (TfR2), hemojuvelin (HJV) and bone 
morphogenetic proteins (BMPs). In addition, hepcidin expression can be regulated by factors 
independent of body iron levels, such as erythroid factors, hypoxia and inflammation. 
Relatively little is known about the suppression mechanisms of hepcidin synthesis. One of the 
identified negative regulators of liver hepcidin expression is matriptase-2 encoded by the 
TMPRSS6 gene. Matriptase-2 is a transmembrane serine protease, which inhibits the 
activation of hepcidin expression by interacting with membrane HJV and cleaving it into 
fragments. Recently SMAD7 was described as a potent inhibitor of HAMP gene expression. 
SMAD7 is an inhibitory SMAD protein that mediates a negative feedback loop to both TGF-β 
and BMP signaling. 
Although both the regulation of the HAMP gene at transcriptional level and the role of 
mature hepcidin peptide have been studied extensively, little is known about the fate of 
precursor prohepcidin within the hepatocytes and in the blood. Prohepcidin was first 
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described as a nuclear peptide with a predicted nuclear localization signal (NLS) sequence, 
but later it was found mainly in the Golgi compartment, or in the cytoplasm showing granular 
cytoplasmic localization.  
In general, mutations in regulatory molecules cause either hepcidin deficiency 
resulting in iron overload, or hepcidin excess with consequent iron deficiency and 
sequestration. HFE, transferrin receptor 2 (TfR2) and hemojuvelin (HJV) are genes mutated 
in human hemochromatosis, and their ablation results in decreased hepcidin responsiveness to 
iron, and relative or absolute hepcidin deficiency. Conversely, mutations in the protease 
TMPRSS6, which are associated with severe iron deficiency, prevent the appropriate decrease 
of hepcidin in the face of iron deficiency. Ferroportin mutations most often cause autosomal 
dominant “ferroportin disease”,manifested as loss of ferroportin function, iron accumulation 
in macrophages with very high levels of serum ferritin, but mild if any liver injury. Rare 
ferroportin mutations cause gain of function due to resistance to hepcidin, with parenchymal 
iron overload similar to that seen in classical hereditary hemochromatosis.  
Hepcidin deficiency has been described in hereditary hemochromatosis (HH) caused 
by mutations in the hepcidin gene (HAMP). Five mutations affecting mature hepcidin have 
been identified to date. These mutations are G71D, C70R, C78T, C82Y and K83R (refer to 
the prepropeptide numbering system). The G71D amino acid substitution is a possible 
modifier in patients with hemochromatosis carrying HFE C282Y mutations. The K83R 
mutation in hepcidin was found in a patient suffering from porphyria cutanea tarda and iron 
overload (unpublished observation). Synthetic G71D and K83R peptides were fully functional 
in vitro assays. Substitutions affecting C70, C78 and C82 cysteines that form disulfide bonds 
in the mature hepcidin cause hemochromatosis. The C70R and C78T mutations which affect 
the third disulfide bond in hepcidin were described in patients with severe juvenile 
hemochromatosis. The C82Y heterozygous mutation with he erozygous R59D mutation cause 
adult onset hemochromatosis. 
Objectives 
To date, the only proven interaction of hepcidin is with the iron exporter molecule 
ferroportin. First we examined whether the disulfide bonds in hepcidin peptide play a role in 
ferroportin-hepcidin interaction. Next, we focused on identifying new protein–protein 
interactions of preprohepcidin, prohepcidin and hepcidin in vivo.  
The main purposes of the work are: 
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• To create four hepcidin mutants by changing one of the cysteine coding nucleotide triplets 
(TGC) to serine coding triplet (TCC). 
• To examine the interactions between mutant hepcidin peptides and ferroportin. 
• To investigate the effect of mutant hepcidin peptides on ferroportin internalization. 
• To identify new protein-protein interactions of preohepcidin, prohepcidin and hepcidin 
using the BacterioMatch Two-Hybrid System.  
• To confirm the protein-protein interactions by in vitro and in vivo methods. 
• To examine these associations on hepatocyte cell lin . 
• To analyze the confirmed interactions in human serum.  
 
Later on, we investigated the regulation of hepcidin expression. Although both the 
transcriptional regulation of the HAMP gene and the role of mature hepcidin peptide have 
been studied extensively, little is known about the fat  of precursor prohepcidin within the 
hepatocytes and in the blood. Prohepcidin was firstdescribed as a nuclear peptide with a 
predicted nuclear localization signal (NLS) sequence, but later it was found mainly in the 
Golgi compartment, or in the cytoplasm showing granul r cytoplasmic localization. Further 
aims of the work are: 
 
• To describe the intracellular localization of prohepcidin. 
• To determine the DNA binding motif of prohepcidin. 
• To investigate the role of prohepcidin in the nucles. 
• To confirm that prohepcidin binds to its promoter HAMP. 
• To examine the effect of prohepcidin overexpression and silencing on the activity of 
HAMP promoter. 
• To explore the effect of A1AT on hepcidin expression. 
 
Results 
The role of hepcidin structure in the hepcidin-ferroportin interaction and in hepcidin- 
mediated ferroportin internalization 
 
Mature hepcidin contains eight cysteine residues at the positions 7, 10, 11, 13, 14, 19, 
22 and 23 which forms four disulfide bridges in a ladder-like configuration. The disulfide 
bonds evolve between the C7-C23, C10-C22, C11-C19 cysteine residues and between the 
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adjacent cysteines C13-C14 forming a vicinal disulfde bridge. These disulfide bonds are 
important in the formation of the stable hairpin struc ure with a distorted beta sheet, exhibiting 
an overall amphipathic structure.  
To investigate the importance of disulfide bridges in the biological role of hepcidin, 
we created four mutant hepcidin by systematically mutating one cystein (TGC) to serine 
(TCC) in each peptide (sequence). The mutated hepcidin peptides were labeled as M1, M2, 
M3 and M4 in order to the position of the amino acid substitution. In the first mutant (M1) the 
C7 cysteine of the first disulfide bridge was mutated o serine, in the second mutant (M2) the 
C10 amino acid was substituted to serine. The M3 and M4 mutants harbor a mutation in the 
C11 amino acid or in the C13 amino acid crucial in the formation of the third or the fourth 
disulfide bridge, respectively. 
 We analyzed the amino acid sequence of the four mutant hepcidin peptides by I-
TASSER server. The prediction shows that the amino acid change (C7 to S) in the first 
disulfide bridge redistributed the overall original molecular structure. The C10-C22 bridge 
remained intact, but the other disulfide bonds rearranged to C13-C19 bridge and for that 
reason, the vicinal bridge was missing. Unlike all the other mutant hepcidin peptides and the 
wild type hepcidin, M1 did not form β-sheet and the N and C termini diverged. Change of the 
C10 cysteine to serine eliminated the second disulfide bridge in the peptide and the vicinal 
bridge was not able to evolve. The lack of C11 result d in a new S-S bridge realigned 
between C13 and C19 while the absence of C13 did not influence the first three disulfide 
bonds formation. 
We examined the in vivo ability of the mutated hepcidin peptides (M1-M4) to bind to 
the whole ferroportin molecule using BacterioMatch Two-Hybrid system. The wild type 
hepcidin and ferroportin expressing bacterial cells gave strong growth rate, indicating that the 
mature hepcidin interacts with the whole ferroportin, as expected. We observed similar 
growth rates when the M2, M3 or M4 mutant hepcidin was expressed in the bacteria instead 
of the wild type hepcidin, while the bacterial cells co-transformed with ferroportin and M1 
mutant hepcidin did not growth at all. This observation suggests that the disulfide bridge 
between the 7 and the 23 cysteine residues of hepcidin has a pivotal role in the interaction 
between hepcidin and ferroportin.  
To obtain an independent support for the crucial importance of the first disulfide 
bridge in the interaction between hepcidin and ferropo tin, we examined if the mutant 
hepcidin peptides expressed in hepatocytes are able to bind to ferroportin located in the 
hepatocyte cell membrane. WRL68 cells were transfected with preprohepcidin or with one of 
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the mutant preprohepcidin sequence containing pTriex3-Neo plasmid DNA. After 24 hours 
we collected the medium and determined its hepcidin co centration to prove that the 
posttranslational maturation of preprohepcidin occurred and the mature peptides were 
secreted. These expressed hepcidin-containing media were added to untransfected WRL68 
cells. After 6 hrs treatment, the concentration of hepcidin in the media were determined again 
to evaluate the ability of secreted hepcidin to bind to ferroportin located in the cell membrane 
of untransfected WRL68 cells. We compared the level of expressed hepcidin protein in the 
media after 6 h and 24 h transfection. The significantly increased level of hepcidin after 24 h 
clearly decreased. The amount of hepcidin in the media collected from wild type or mutated 
hepcidin-overexpressing cells elevated compared to the hepcidin level of the medium of 
untransfected cells proving increased hepcidin expression and secretion due to transfection 
(129-222% compared to the control cells). When we transferred these media onto 
nontransfected WRL68 cells for 6 h, the levels of secreted wild type, M2, M3 and M4 
hepcidin decreased to 82%, 82%, 74% and 47% respectively. This change was due to the fact 
that the peptide bound to ferroportin.  On the contrary, there was no significant change 
observed in the secreted hepcidin peptide concentration in case of M1 hepcidin peptide. These 
data corroborate with our previous results indicating that the M1 mutant lacking the first 
disulfide bridge was not able to bind to its receptor ferroportin. 
Since the secreted hepcidin regulates iron homeostasis by interacting with ferroportin, 
which results in internalization of ferroportin and loss of its function, finally we tested the 
ability of the mutant hepcidin peptides to induce ferroportin internalization in vivo.  
WRL68 cells were transfected with preprohepcidin or with one of the mutant 
preprohepcidin coding pTriex3-Neo plasmid and were treated the same way as described 
above. Cells were fractionated after 6 h and 24 h long treatment with secreted hepcidin 
peptides containing medium. Then the isolated cytosol and membrane fractions were probed 
with anti-FP antibody. Untreated WRL cells were used as negative control and cells treated 
with wild type hepcidin containing medium were used as positive control for the 
internalization assay. Internalization of ferroportin was generated by mature hepcidin within 6 
h. As it was expected, the M1 hepcidin internalization was failed, since this mutant was not 
able to bind to ferroportin. Surprisingly the other th ee mutant peptides M2, M3, M4 were not 
able to generate the internalization of ferroportin either.  
To confirm the result of the internalization assay the iron (FeII) content of the treated 
WRL cells was determined. The results corroborated our previous observation: only the WRL 
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cells treated with wild type hepcidin showed elevatd iron concentration compared to the 
control cells. Treatment with the mutant hepcidin peptides had no effect on iron export.     
Summarizing our results, here we demonstrated that all he four intact disulfide 
bridges in hepcidin peptide are essential to its inernalization activity, and the first disulfide 
bond has a crucial role in hepcidin-ferroportin interaction.  
 
Interactions of preprohepcidin and prohepcidin with alpha 1-antitrypsin 
 
The interactions of preprohepcidin and hepcidin with hepatocyte proteins were 
screening with BacterioMatch Two-Hybrid system. Preprohepcidin exhibited binding to 
transthyretin (or prealbumin), a serum protein know as a thyroid hormone carrier molecule. 
We also found the association of preprohepcidin with a-1 acid protein (orosomucoid), a major 
plasma protein with unknown function. The level of this protein is elevated in the blood in the 
case of inflammation, and it is used as a diagnostic marker in inflammatory diseases (acute 
phase protein). The strongest association of preproh cidin proved to be with A1AT, a 
member of the serine protease inhibitor (serpin) family. A1AT was ‘fished out’ at the 
screenings more times than any other interacting protein (one-third of all sequenced cDNA 
clones), indicating a consistent and potentially relevant interaction with preprohepcidin. 
However, a more abundant representation of A1AT clones, when compared with other 
positive clones, cannot be excluded. The strong binding between preprohepcidin and A1AT 
was confirmed when the two proteins were co-expressed in BacterioMatch competent cells. 
As furin, a serine protease involved in the maturation of hepcidin, is also inhibited by A1AT, 
we considered this as a potentially important observation. This cotransformation was repeated 
with the same protease inhibitor and either the 60-AA prohepcidin (without the targeting 
sequence) or the 25-AA-containing mature hepcidin. We detected the growth of the 
cotransformed BacterioMatch strain in the case of pr hepcidin, but not with mature hepcidin. 
We found that the protease inhibitor molecule binds selectively to the preprohormone and 
prohormone, but not to the processed hepcidin or tothe targeting sequence of preprohepcidin. 
There were other proteins (cytochrome P450, ATP⁄ADP translocase, enoyl-CoA 
hydratase) which gave weak interactions with preprohepcidin. Alignment of the coding 
regions of these proteins did not show significant similarities. Nor could we identify common 
structural domains that may provide further clues to preprohepcidin binding. 
BacterioMatch screening carried out with the mature 25-AA peptide resulted in 
significantly fewer positive clones when compared with the screening with the 
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preprohormone. None of these proteins was identical with the screening results of the 84-AA 
peptide. The only strong and consistent interaction of the mature peptide was with membrane 
protein CD74. Further experiments are needed to evaluate this finding. 
The most consistent and strongest interaction occurred with the serine protease 
inhibitor A1AT. This association was further tested by both in vivo and in vitro methods to 
evaluate its significance. 
Both preprohepcidin and A1AT were cloned into inducible plasmids and expressed in 
bacteria. Preprohepcidin carried a glutathione S-transferase (GST) fusion tag for attachment 
to an affinity purification column. This column was u ed to pull down expressed A1AT from 
bacterial lysate or human serum. The interaction of A1AT with preprohepcidin was verified 
by the elution of protein complexes from the column, followed by western blotting developed 
with anti-A1AT IgG. The in vitro binding of the two molecules appeared to be specific, as 
GST-carrying affinity columns produced only negligible quantities of A1AT tethering. 
Next, we studied the influence of the overexpression r downregulation of 
preprohepcidin on the A1AT mRNA level. We transfected WRL68 cells with preprohepcidin ⁄ 
pTriex3-Neo plasmid and were able to demonstrate a 470-fold increase in the copy number of 
preprohepcidin mRNA by real-time quantitative PCR. Using antisense RNA, we reduced the 
preprohepcidin mRNA level to 63%. The same samples w re processed for A1AT mRNA 
level measurement. We found that the A1AT mRNA level increased by more than two-fold 
when preprohepcidin was overexpressed. Even more significantly, the 37% decrease in 
preprohepcidin expression caused by antisense RNA coincided with a nearly fourfold 
reduction of A1AT mRNA. These data suggest a regulatory link between the preprohormone 
and antiprotease expression, underlining a physiologically important relationship between the 
hormone and A1AT. 
Next, we studied the interaction of prohepcidin and plasma A1AT in the circulation. 
We carried out ultrafiltration assays with sera collected from presumably healthy volunteers. 
After measuring the prohepcidin level with ELISA, the serum was filtered through a 30 kDa 
cut-off membrane and the prohepcidin level was determined in the filtrate (first ultrafiltrate). 
Prohepcidin itself did not bind to the filter of the Microcon tube, and A1AT did not appear in 
the serum ultrafiltrate (data not shown). We found that the serum prohepcidin level was 210 
µg/ml, whereas the first filtrate contained 71.7 µg/ml (34% of the total). Although these data 
prove that normally more than 60% of the total prohepcidin is bound to serum proteins larger 
than 30 kDa, no evidence could be found that A1AT binds prohepcidin significantly. To 
demonstrate the capability for binding ‘free’ (filterable) prohepcidin to A1AT, the above 
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experiment was repeated after the addition of 1.5 g/L A1AT to the first serum ultrafiltrate. 
The prohepcidin concentration in the second ultrafite was further reduced to 46.6 µg/ml 
(22% of the total), or to 65% of the first filtrate.  
To reveal the specificity of the preceding binding reaction, we performed 
coimmunoprecipitation assays. We attached A1AT antibody to a column of CNBr activated 
Sepharose beads, and incubated this with serum. Sepharose beads were washed and A1AT-
associated proteins were eluted with Laemmli buffer. Next, we probed the eluent with anti-
hepcidin IgG. Results of the dot blot displayed strong positive signals, indicating that A1AT 
and prohepcidin associated in vivo in the serum. Ultrafiltrated ‘free’ prohepcidin by itself 
gave no binding to the activated Sepharose beads.  
Similar affinity purification was carried out using the ZipTip method, in which A1AT 
antibody was attached to the C18 column of ZipTip and incubated with serum, as in the 
previous experiment. The eluted sample was analyzed on a MALDI-TOF mass spectrometer. 
The spectrum was compared with that obtained in the cas  of bacterially expressed His-tagged 
prohepcidin with a molecular weight of 7760.08 Da. In the latter case, two major peaks 
appeared in the spectrum, at 1410.96 and 6349.12 m/z. The peak at 1410.96 m/z corresponds 
to a fragment of 6X His and 5 AA from the C-terminal end of prohepcidin 
(MCCKTHHHHHH). The affinity-purified prohepcidin from serum gave the same 6349.14 
m/z peak as above, suggesting a similar fragmentation of the prohormone. In this experiment, 
the C-terminal 5-AA (MCCKT) fragment does not appear, s detection was performed 
between 1000 m/z and 7500 m/z to exclude matrix peaks in the low mass ranges. Not only 
does this affinity purification assay reveal that A1AT binds prohepcidin, but it also confirms 
that the whole prohepcidin molecule is involved in the reaction. 
 
Autoregulation: a new way of regulating prohepcidin expression 
 
We transiently transfected WRL68 cells with pTriex3-Neo plasmid containing the 
HAMP gene in order to overexpress prohepcidin. Intracellular localization of prohepcidin was 
studied by using in vivo immunocytochemistry. The cells were labeled with anti-prohepcidin 
antibody and imaged using a laser scanning confocal microscope to allow imaging of cellular 
cross-sections. In addition to the granular cytoplasmic staining which may suggest that the 
peptide is concentrated within vesicles in the cytoplasm, prohepcidin was also found in the 
nuclear region of hepatocytes. 
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The nuclear localization of prohepcidin raised the possibility that it may act as a factor 
influencing its own gene expression. In order to predict the DNA binding properties of 
prohepcidin we used an SVM-based prediction algorithm. The results of the prediction for 
prohepcidin and hepcidin are shown in Table 1. The SVM scores for prohepcidin based on 
amino acid composition (1.47) and based on position-specific scoring matrix (PSSM) (1.07) 
were both higher than the threshold (1.0), corresponding to the highest specificity setting, 
predicting DNA binding by prohepcidin. Notably, the analysis of the 25-amino acid hepcidin 
sequence predicted no DNA binding (SVM scores 0.03 and 0.16).  
To confirm the ability of prohepcidin to bind to DNA, we performed chromatin-
immunoprecipitation assay (ChIP). Formaldehyde-crosslinked prohepcidin-bound DNA 
fragments were immunoprecipitated from WRL68 cells overexpressing prohepcidin-His 
peptide using anti-His antibody. ChIP assay revealed significant amount of HAMP promoter 
bound to prohepcidin, raising the possibility of an interaction between prohepcidin and the 
promoter region of its own gene. 
To obtain independent support for the DNA binding property of prohepcidin, we 
developed a PCR-based promoter binding assay and we further analyzed the interaction 
between the peptide and the promoter region of HAMP gene. The promoter binding assay was 
performed using WRL68 cells overexpressing prohepcidin-His peptide. The peptide was 
purified from the nuclear extract using anti-His antibody-coated CNBr Sepharose beads, then 
the washed beads were incubated with HAMP promoter. The peptide-DNA complex was 
eluted from the surface of the beads, and the eluate w s used as a template in a PCR reaction 
with promoter specific primers for the detection of prohepcidin-bound HAMP promoter. As 
our results show, we detected promoter binding only in the sample in which prohepcidin-His 
was incubated with the HAMP promoter. We did not observe promoter binding in case of 
controls.  
In a similar experiment we first pre-incubated the HAMP promoter with the nuclear 
extract of WRL68 cells overexpressing prohepcidin-Hs peptide, and then we isolated the 
HAMP-prohepcidin-His complex using anti-His CNBr Sepharose beads. Similarly to our 
previous result, we detected promoter binding only from the sample in which the prohepcidin-
His peptide and the HAMP promoter were present. These results clearly suggest a specific 
interaction between prohepcidin and its own promoter. 
However, it is possible that prohepcidin did not bind to the beads alone, but as part of 
a larger complex that might contain other DNA-binding protein(s). The presence of such 
protein(s) could also explain the positive result of the HAMP promoter binding assay. To find 
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out whether prohepcidin can bind to the promoter region of the HAMP gene by itself or as a 
member of a complex, we expressed prohepcidin-His in BL21 bacterial cells in order to 
prevent the potential formation of a complex with nuclear DNA-binding proteins. The 
immunoprecipitated peptide was subjected to the promoter binding assay using exactly the 
same method as in previous experiments. Results show t at we could amplify the HAMP 
promoter region only from the sample which contained the bacterially expressed prohepcidin-
His peptide, while DNA binding was not detected in the control samples. These results 
confirm that prohepcidin alone is able to bind to theHAMP promoter. 
Having identified prohepcidin as a HAMP promoter binding peptide, we turned our 
attention to confirming whether this interaction has  HAMP gene regulatory effect. To 
determine the effect of prohepcidin binding on the HAMP gene expression we compared the 
HAMP promoter activity at different intracellular prohepcidin levels.  
To increase the constitutive level of prohepcidin in WRL68 cells, we transiently 
transfected the cells with pcDNA3.1 expression plasmid containing preprohepcidin cDNA. In 
addition, the intracellular prohepcidin level was reduced by transfecting the cells with 
pcDNA3.1 plasmid containing preprohepcidin antisense DNA. To help the quantification of 
the HAMP promoter activity we cloned the 942-bp fragment of the HAMP promoter as a 
transcriptional fusion with firefly luciferase, resulting in the pGL3/HAMP promoter construct 
that was cotransfected with the pcDNA3.1/preprohepcidin or the antisense construct into 
WRL68 cells. Expression levels of preprohepcidin mRNA were measured by real-time PCR 
and the activation of the promoter was determined by Luciferase assay. 
At normal prohepcidin level the HAMP promoter-luciferase reporter vector exhibited 
basal activity in WRL68 hepatocytes. In cells harboring the overexpression construct the 
preprohepcidin mRNA level was 435-fold higher and the activity of the HAMP promoter 
decreased to 52% of the original level. An even more significant effect was detected upon 
diminishing the amount of prohepcidin. When we decreased the amount of intracellular 
prohepcidin to 63% of the normal level, the activity of the HAMP promoter increased up to 
5.2-fold compared to the original level.  
These results are specific for the pro form of the hormone, as overexpressing mature 
hepcidin in WRL68 cells did not result in decreased HAMP promoter activity. To verify 
whether the pro region alone is sufficient to influence the activity of the HAMP promoter, we 
created a fusion protein containing the pro region of prohepcidin fused to a cytoplasmic 
enzyme, GAPDH. Overexpression of this protein in WRL68 cells did not change the activity 
of the HAMP promoter, indicating that the pro region alone is not sufficient for the DNA 
 14 
binding activity. Finally, the elevated or decreased l vel of prohepcidin had no effect on the 
activity of the promoter region of transin gene, indicating that the interaction between 
prohepcidin and HAMP promoter is specific. These observations suggest that prohepcidin 
regulates its own gene expression by downregulating its promoter activity. 
We have previously shown that prohepcidin specifically binds to A1AT in the cell and 
in the serum, indicating the role of A1AT in the posttranslational modification of prohepcidin. 
In order to find out if this interaction has any influence on the HAMP gene expression, we 
increased the amount of A1AT in WRL68 cells and analyzed its effect on HAMP promoter 
activity using Luciferase assay. When we overexpressed A1AT, the activity of the HAMP 
promoter increased up to 3.3-fold compared to the HAMP promoter activity in cells with 
normal A1AT level. The elevated promoter activity suggests that the A1AT-bound 
prohepcidin may not be able to downregulate HAMP gene expression. 
To study the effect of A1AT on the binding of prohepcidin to the HAMP promoter, we 
overexpressed A1AT in WRL68 cells, purified the protein by immunoprecipitation and 
analyzed the sample with dot blot using anti-hepcidin antibodies. As expected, we could 
detect not only the isolated A1AT, but the A1AT-bound prohepcidin as well. Next the 
immunoprecipitated A1AT-prohepcidin complex was subjected to a HAMP promoter binding 
assay. Our observation was that neither prohepcidin-free A1AT (bacterially expressed A1AT) 
nor A1AT-bound prohepcidin (from WRL68 cells) were able to bind to the HAMP promoter. 
Taken together, these results suggest that only the non-A1AT-bound prohepcidin 
binds to the promoter site, and as a consequence, downregulates HAMP gene expression.  
 
Summary 
Hepcidin plays a crucial role in iron homeostasis. To date, the only well known protein which 
has an interaction with hepcidin is the iron exporter ferroportin. The hepcidin-mediated 
ferroportin internalization is well described, although the role of disulfide bonds of hepcidin 
peptide is still unknown.   
• We proved that the first (C7-C23) disulfide bond is essential in hepcidin-ferroportin 
interaction. 
• We demonstrated that all the four disulfide bridges are necessary for hepcidin-
mediated ferroportin internalization. The substitution of one of the conserved cysteine 
residues eliminated the biological activity of hepcidin.  
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Taken together, these results suggest that in case of the known hepcidin mutations 
affecting the conserved cysteine residues (C70R and C78T)  hepcidin is able to bind to 
ferroportin but not able to cause its internalization.  
We were interested in identifying new protein-protein interactions of preprohepcidin, 
prohepcidin and mature hepcidin. These new interactions could influence on iron homeostasis 
and hepcidin regulation.  
 
• We demonstrated that the serine protease A1AT gives strong interaction with 
preprohepcidin and prohepcidin. 
• We also demonstrated an interaction between preprohcidin and alpha 1- acid 
glycoprotein, and preprohepcidin and transthyretin. 
• We proved that the mRNA expression of A1AT shows parallel pattern with 
preprohepcidin mRNA overexpression and silencing.  
• We confirmed the specificity of A1AT-preprohepcidin interaction in hepatocyte cell 
line with in vivo (crosslinking) and in vitro (GST pull down) methods.  
• We demonstrated that A1AT-prohepcidin binding is specific in the serum (ELISA, 
coimmunoprecipitation, serum ultafiltration assay, MALDI TOF).  
• We proved that mature hepcidin shows strong interacions with ferritin heavy chain 
and CD74 protein. 
 
  Our results demonstrated that the serine protease inhibitor A1AT binds preprohepcidin 
within the cell during maturation. Furthermore, A1AT binds prohepcidin in the plasma. This 
observation may explain the presence of prohormone in the circulation, as well as the post-
translational regulation of the mature hormone level in the blood.  
Although both the regulation of the HAMP gene at transcriptional level and the role of 
mature hepcidin peptide have been studied extensively, little is known about the fate of 
precursor prohepcidin within the hepatocytes and in the blood. We aimed to determine the 
localization of prohepcidin within the hepatocytes and reveal its function.  
 
• We showed that prohepcidin is located in the cytosol a  well as in the nucleus of 
WRL68 hepatocyte cells. 
• We confirmed that prohepcidin possesses a DNA-binding motif using SVM based 
algorithm.  
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• We proved that prohepcidin binds specifically to its own promoter HAMP by 
chromatin immunoprecipitation and by a protein-DNA binding method developed by 
our research group.  
• We demonstrated that prohepcidin is able to bind to its promoter by itself without any 
other DNA-binding proteins. 
• We confirmed that prohepcidin is able to regulate its own gene expression.  
• We proved that changes in the level of A1AT influenc  HAMP gene expression.  
• We demonstrated that prohepcidin bound to A1AT is not able to interact with HAMP 
promoter; therefore prohepcidin is not capable to regulate its own gene expression.  
 
These results suggest that prohepcidin is localized not only to the cytoplasm but also 
to the nucleus of hepatocytes. The nuclearly located p ptide binds to the HAMP promoter, 
causing decreased promoter activity. Moreover, the known interaction between A1AT and 
prohepcidin inhibits this autoregulatory effect. We d scribed a novel role of prohepcidin in 
the regulation of HAMP gene expression which may contribute to better understanding of the 
regulation of iron homeostasis. 
 
Acknowledgement 
 
I would like to thank Dr. Katalin Sipos the support and guidance I received.  
I would like to thank Prof. Dr. Attila Miseta and Prof. Dr. Gábor L. Kovács for managing my 
work and giving support and useful advices. 
I would like to thank the technical help I recieved from all my colleagues at the Institute of 
Laboratory Medicine, the Department of Forensic Medicine and the Department of 
Biochemistry and Medical Chemistry. 
I would like also thank dr. Zsuzsanna Fekete for the never ending encouragement and advices.  
I would like to thank Dr. Beáta Polgár for her help and advices.   
 17 
Publications 
Publications in the topic/A témában közölt publikációk 
 
Articles/Cikkek 
E. Pandur, J. Nagy, V. S. Poór, Á. Sarnyai, A. Huszár, A. Miseta, K. Sipos: 
Alpha-1 antitrypsin binds preprohepcidin intracellularly and prohepcidin in the serum 
FEBS Journal. 2009; 276: 2012-2021. IF 3,042 
 
J. Nagy, L. Lakner, V. S. Poór, E. Pandur, Gy. Mózsik, A. Miseta, K. Sipos:  
Serum prohepcidin levels in chronic inflammatory bowel diseases 
Journal of Crohn's and Colitis 2010; 4: 649-653. IF 1,729 
 
E. Pandur, K. Sipos, J. Nagy, V.S. Poór, L. Grama, A. Miseta and Zs. Fekete: 
Prohepcidin binds to HAMP promoter and regulates its own gene expression in WRL68 cell line 
Biochimie. 2011; 
 
E. Pandur, J. Nagy, V.S. Poór, Zs. Fekete, A. M. Peti, A. Miseta, K. Sipos:  
The higher structure of hepcidin is essential for binding to ferroportin  
Peptides. 2011; 
 
Published abstracts/Idézhető absztraktok 
 
E. Pandur, J. Nagy, V. S. Poór, A. Miseta, K. Sipos:  
In vivo interactions of preprohepcidin and mature hepcidin with ferroportin  
33. FEBS Congress Athens, Greece, June 28 -July 3. 2008. FEBS Journal. 2008; 275 s1: 316. IF 3,14 
 
V. S. Poór, E. Pandur, J. Nagy, K. Sipos, A. Miseta:  
Protein-protein interaction screening with BacterioMatch system 
33. FEBS Congress, Athens, Greece, June 28 -July 3. 2008. FEBS Journal. 2008; 275 s1: 424. IF 3,14 
 
 J. Nagy, E. Pandur, V. S. Poór, B. Debreceni, K. Sipos:  
The function of human RNase L Inhibitor in translation 
33. FEBS Congress Athens, Greece June 28 -July 3. 2008. FEBS Journal 2008; 275. s1: 127. IF 3,14 
 
Oral presentations/Előadások 
 
Sipos K.; Pandur E.; Nagy J.; Poór V. S.: A hepcidin, egy vasanyagcserét szabályozó hormon 
jellemzése 
37. Membrántranszport Konferencia Sümeg máj. 22-25.  2007. 
 
V.S. Poór, E. Pandur, J. Nagy, A. Miseta, K. Sipos: New protein-protein interactions of the human 
hepcidin 
The 5th International Conference of Postgraduate Medical Students Hradec Králové Czech Republic 
nov. 27-29. 2008. 
 
Miseta A.; Pandur E.; Nagy J.; Huszár A.; Sipos K.: Az alfa-1 antitripszin szerepe a hepcidin 
érésében 
Erdélyi Múzeum Egyesület, Orvos és Gyógyszerésztudományi Szakosztály, XIX. Tudományos 
Ülésszak Marosvásárhely Románia ápr. 23-25. 2009. 
 18 
Posters/Poszterek 
 
Pandur E.; Nagy J.; Szabó A.; Montskó G.; Radnai B.; Sipos K : A hepcidin expressziójának 
intracelluláris szabályozása  
V. Magyar sejtanalitikai konferencia Budapest máj. 4-6. 2006.  
 
Pandur E.; Nagy J.; Szabó A.; Montskó G.; Peti M. A.; Sipos K.: Ferroportin egy hepcidin hormon 
által szabályozott vas transzporter- Előadásra kiválasztott poszter 
36. Membrán-Transzport konferencia Sümeg máj. 23-26. 2006. 
 
Pandur E.; Nagy J.; Montskó G.; Peti M. A.; Sipos K.: A hepcidin, egy vasanyagcserét szabályozó 
hormon vizsgálata  
A Magyar Biokémiai Egyesület 2006. évi Vándorgyűlése Pécs aug. 30- szept. 2. 2006. 
 
Pandur E.; Nagy J.; Poór V. S.; Peti M. A.; Sipos K.: Hepcidin interakciója más fehérjékkel 
37. Membrán-Transzport konferencia Sümeg máj. 22-25. 2007. 
 
Poór V. S.; Pandur E.; Nagy J.; Peti M. A.; Sipos K.; Miseta A.: A hepcidin antimikrobiális 
hatásmechanizmusának vizsgálata 
37. Membrán-Transzport konferencia Sümeg máj. 22-25. 2007. 
 
Pandur E.; Nagy J.; Poór V. S.; Sipos K.: C/EBP alfa és SMAD4 transzkripiós faktorok szerepe a 
vasanyagcsere szabályozásában WRL68 sejttenyészetben 
XVI. Nemzetközi Semmelweis Szimpózium és VI. Magyar Sejtanalitikai Konferencia Budapest nov. 
15-17. 2007. 
 
Poór V. S.; Pandur E.; Nagy J.; Sipos K.: A hepcidin és ferroportin expressziójának változása CaCo, 
WRL és HepG2 sejtekben 
XVI. Nemzetközi Semmelweis Szimpózium és VI. Magyar Sejtanalitikai Konferencia Budapest nov. 
15-17. 2007. 
 
Nagy J.; Lakner L.; Pandur E.; Poór V. S.; Mózsik Gy.; Sipos K.; Miseta A.: Prohepcidinszint 
meghatározása gyulladásos bélbetegségekben 
XVI. Nemzetközi Semmelweis Szimpózium és VI. Magyar Sejtanalitikai Konferencia Budapest nov. 
15-17. 2007. 
 
Pandur E.; Nagy J.; Poór V. S.; Miseta A.; Sipos K.: A hepcidin és a ferroportin kapcsolatának 
vizsgálata BacterioMatch Two-Hybrid rendszerrel 
38. Membrán-Transzport konferencia Sümeg máj. 20-23. 2008. 
 
Nagy J.; Pandur E.; Poór V. S.; Rab A.; Sipos K.; Miseta A.: C/EBP alfa és SMAD4 transzkripciós 
faktorok hatása a hepcidin expressziójára 
38. Membrán-Transzport konferencia Sümeg máj. 20-23. 2008. 
 
Poór V. S.; Pandur E.; Nagy J.; Rideg O.; Miseta A.; Sipos K.: Protein-protein kapcsolatok vizsgálata 
BacterioMatch rendszerrel 
38. Membrán-Transzport konferencia Sümeg máj. 20-23. 2008. 
 
Pandur E., Nagy J., Poór V. S., Sarnyai Á., Rapp J., Miseta A., Sipos K.:A hepcidin promóterének 
aktivitás-vizsgálata luciferáz rendszerrel  
A VIII. Magyar Genetikai Kongresszus és a XV. Sejt- és Fejlődésbiológiai Napok Nyíregyháza ápr. 
17-19. 2009. 
 
Poór V. S., Pandur E., Nagy J., Sarnyai Á., Miseta A., Sipos K.: A hepcidin kapcsolata két akut fázis 
fehérjével 
 19 
A VIII. Magyar Genetikai Kongresszus és a XV. Sejt- és Fejlődésbiológiai Napok Nyíregyháza ápr. 
17-19. 2009. 
 
Pandur E.; Nagy J.; Poór V. S.; Montskó G.; Sarnyai Á.; Miseta A.; Sipos K.: Az α1-antitripszin 
szerepe a hepcidin érésében 
39. Membrán-Transzport konferencia Sümeg máj. 19-22. 2009. 
 
Poór V. S, Pandur E, Nagy J, Rapp J, Sarnyai Á, Miseta A, Sipos K: Hepcidin mutációk: a térbeli 
szerkezet és a biológiai aktivitás összefüggése 
39. Membrán-Transzport Konferencia Sümeg máj. 19-22. 2009. 
 
Nagy J, Pandur E, Poór V. S, Sarnyai Á, Miseta A, Sipos K: A hemszintézis és a hepcidin 
transzkripció szabályozásának kapcsolata 
39. Membrán-Transzport Konferencia Sümeg máj. 19-22. 2009. 
 
Frank D, Pandur E, Poór V. S, Nagy T, Sarnyai Á, Miseta A: A hepcidin kimutatása a nagy 
nyálmirigyekből  
39. Membrán-Transzport Konferencia Sümeg máj. 19-22. 2009. 
 
Pandur E., Nagy J., Poór V.S., Rapp J., Miseta A., Sipos K., Fekete Zs.: A hepcidin gén (HAMP) 
expresszió szabályozásának új mechanizmusa hepatocitákban - Előadásra kiválasztott poszter 
40. Membrán-Transzport Konferencia Sümeg máj. 18-21. 20 0. 
 
Poór V.S., Pandur E., Nagy J., Rácz E., Miseta A., Sipos K.: A hepcidin és az alfa-1 savas 
glikoprotein interakciója 
40. Membrán-Transzport Konferencia Sümeg máj. 18-21. 20 0. 
 
Further posters/További poszterek 
 
B. Sümegi; A. Pálfi; K. Kovács; K. Hantó; P. Deres; E. Pandur; E. Bognár; A. Toth; K. Toth: 
Akt/GSK-3β, PKC and MAP kinase cascades contribute to the protective effect of PARP inhibition 
PARP 2005 Symposium Newcastle England oct. 5-7. 2005. 
 
Pandur E.; Nagy J.; Szabó A.; Montskó G.; Sipos K.: A mitokondrium jelentősége a transzláció 
szabályozásában humán sejtekben 
36. Membrán-Transzport konferencia Sümeg máj. 23-26. 2006. 
 
Nagy J.; Pandur E.; Debreceni B.; Montskó G.; Sipos K.: Egy közös molekula szerepe a riboszómális 
RNS érésben élesztő és emlős sejtekben 
A Magyar Biokémiai Egyesület 2006. évi Vándorgyűlése Pécs aug. 30- szept. 2. 2006. 
 
Nagy J.; Pandur E.; Debreceni B.; Poór V. S.; Sipos K.: Humán- élesztő hibrid RNáz inhibitor 
funkcionális vizsgálata 
37. Membrán-Transzport konferencia Sümeg máj. 22-25. 2007. 
 
Polgár B.; Pandur E.; Gajdos G.; Fekete Zs.; Berki T.; Jerry N. van Dijken P.; Szekeres-Barthó J.: 
PIBF specifikus poli- és monoklonális antitestek alkalmazása az immunbiológiai kutatásokban 
Magyar Immunológiai Társaság XXXIX. Vándorgyűlése Szeged nov. 3-5. 2010. 
 
Bogdán Á.; Polgár B.; Pandur E.; Szekeres-Barthó J.: A PIBF mRNS expressziós mintázatának 
vizsgálata terhességhez asszociált szövetekben  
A Magyar Immunológiai Társaság XXXIX. Vándorgyűlése Szeged nov. 3-5. 2010. 
